Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

ClinicalTrials.gov ID: NCT02301104

Public ClinicalTrials.gov record NCT02301104. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.

Study identification

NCT ID
NCT02301104
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Taiho Oncology, Inc.
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2015 (Type not available)
Primary completion
Jun 2016 (Actual)
Completion
Jun 2016 (Actual)
Last update posted
Sep 5, 2024

2015 – 2016

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Mayo Clinic Scottsdale Arizona 85259 —
Duarte Clinical Site Duarte California 91010 —
Santa Monica Clinical Site Santa Monica California 90404 —
Baltimore Clinical Site Baltimore Maryland 21231 —
Boston Clinical Site Boston Massachusetts 02111 —
Cleveland Clinical Site Cleveland Ohio 44195 —
Pittsburgh Clinical Site Pittsburgh Pennsylvania 15232 —
Dallas Clinical Site Dallas Texas 75246 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02301104, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 5, 2024 · Synced Nov 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02301104 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →